Elan's New Drug Reduces Severity of Cervical Dystonia

December 1999
Worldwide Biotech;Dec99, Vol. 11 Issue 12, p2
Trade Publication
Looks at the results of the studies conducted by Elan Pharmaceuticals Inc. of South San Francisco, California on the drug treating cervical dystonia. Evaluation of Elan's Botulinum Toxin Type B Injectable Solution; Phases of the clinical trial; Effectiveness.


Related Articles

  • Dosage discovery. Hewitt, Allison // Pharmaceutical Executive;Dec97, Vol. 17 Issue 12, p88 

    Reports on the result of Elan's multicenter, double-blind, placebo-controlled Phase II safety, tolerability, dose-selection, and efficacy study of Neurobloc in patients with cervical dystonia. Comparison of placebo-treated patients to those receiving single injection of Neurobloc; Duration of...

  • Morphine Oral - Elan Corporation: Avinzaâ„¢.  // Drugs in R&D;2002, Vol. 3 Issue 3, p208 

    Adis Comments Elan Corporation is developing an oral, once daily, controlled-release formulation of morphine sulphate (formerly called Morphelanâ„¢) for use in pain management therapy. Elan Corporation has been granted marketing approval by the FDA for Avinzaâ„¢ (morphine sulphate...

  • Clinic Roundup.  // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p8 

    The article reports on the initiation of a Phase II trial of oral ELND005 by Elan Corp. plc, the licensing partner of Transition Therapeutics Inc., as an adjunctive maintenance treatment of bipolar I disorder patients to delay the time to occurrence of mood episodes.

  • Call for Elan to publish Alzheimer's trial details. Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S. // Nature;4/18/2002, Vol. 416 Issue 6882, p677 

    Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the...

  • Elan and Wyeth to take Alzheimer's drug to phase III.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled...

  • Isis Starts Clinical Trials for Hepatitis C Drug. Webb, Marion // San Diego Business Journal;4/1/2002, Vol. 23 Issue 13, p10 

    Reports the clinical trials for an experimental hepatitis C drug by Isis Pharmaceuticals Inc. and Elan Corp. in Carlsbad, California. Evaluation on the safety and tolerance of the compound; Details of the drug administration on patients; Views of F. Andrew Dorr, vice president of Isis on drug...

  • J&J Deal Lifts Overhang on Elan Stock; Investors Cautious. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple...

  • In Brief. L.F.; A.B.; J.F. // Nature Biotechnology;Apr2002, Vol. 20 Issue 4, p327 

    Reports on various biotechnology business and regulatory news as of April 2002. Elan Corp.'s termination of clinical trials of its experimental vaccine for the treatment of Alzheimer's disease; Naming of Lester Crawford as deputy commissioner of the U.S. Food and Drug Administration;...

  • Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion. Hollingsworth, Catherine // BioWorld International;4/23/2008, Vol. 13 Issue 17, p6 

    The article discusses the suspension of the Phase II trial study of the ACC-011 compound for Alzheimer's disease in 2008. The compound is being developed by Elan Corp. plc and Wyeth Pharmaceuticals. An announcement regarding the suspension was posted on April 17 on the Web site,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics